3/26
08:00 am
eols
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Low
Report
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
3/20
02:27 pm
eols
Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028 [Seeking Alpha]
Low
Report
Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028 [Seeking Alpha]
3/19
04:42 pm
eols
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements [Yahoo! Finance]
Low
Report
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements [Yahoo! Finance]
3/19
04:42 pm
eols
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine [Yahoo! Finance]
Low
Report
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine [Yahoo! Finance]
3/11
07:35 am
eols
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock [Yahoo! Finance]
Medium
Report
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock [Yahoo! Finance]
3/11
07:29 am
eols
Evolus prices stock offering to raise about $50M [Seeking Alpha]
Medium
Report
Evolus prices stock offering to raise about $50M [Seeking Alpha]
3/11
07:00 am
eols
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
Low
Report
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
3/10
09:37 am
eols
Analyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its Full-Year Report [Yahoo! Finance]
Low
Report
Analyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its Full-Year Report [Yahoo! Finance]
3/8
04:05 pm
eols
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/8
03:46 pm
eols
Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/7
10:47 pm
eols
Evolus Inc (EOLS) Reports Record Revenues in Q4 and Full Year 2023, Eyes Profitability in 2024 [Yahoo! Finance]
Low
Report
Evolus Inc (EOLS) Reports Record Revenues in Q4 and Full Year 2023, Eyes Profitability in 2024 [Yahoo! Finance]
3/7
04:40 pm
eols
Evolus GAAP EPS of -$0.21 in-line, revenue of $61M in-line [Seeking Alpha]
Low
Report
Evolus GAAP EPS of -$0.21 in-line, revenue of $61M in-line [Seeking Alpha]
3/7
04:09 pm
eols
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance [Yahoo! Finance]
Low
Report
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance [Yahoo! Finance]
3/7
04:05 pm
eols
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
Medium
Report
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
3/1
02:44 pm
eols
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Low
Report
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
3/1
08:45 am
eols
Evolus Announces Results from European Head-to-Head Filler Trial [Yahoo! Finance]
Low
Report
Evolus Announces Results from European Head-to-Head Filler Trial [Yahoo! Finance]
3/1
08:30 am
eols
Evolus Announces Results from European Head-to-Head Filler Trial
Low
Report
Evolus Announces Results from European Head-to-Head Filler Trial
2/27
08:43 am
eols
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences [Yahoo! Finance]
Low
Report
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences [Yahoo! Finance]
2/27
08:30 am
eols
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
Low
Report
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
2/22
04:30 pm
eols
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
Medium
Report
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
2/20
05:44 am
eols
Facial Injectable Market Demand to Hit USD 40.4 Billion by 2033 | Globally at 11.1% CAGR [Yahoo! Finance]
Low
Report
Facial Injectable Market Demand to Hit USD 40.4 Billion by 2033 | Globally at 11.1% CAGR [Yahoo! Finance]
2/9
04:05 pm
eols
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/6
03:52 am
eols
Daewoong Pharmaceutical Announces 2023 Financial Results [Yahoo! Finance]
Low
Report
Daewoong Pharmaceutical Announces 2023 Financial Results [Yahoo! Finance]
2/2
09:31 pm
eols
Evolus Inc Director Karah Parschauer Sells 11,931 Shares [Yahoo! Finance]
Medium
Report
Evolus Inc Director Karah Parschauer Sells 11,931 Shares [Yahoo! Finance]
1/29
07:28 am
eols
Evolus, Inc. (NASDAQ: EOLS) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating. They now have a $16.00 price target on the stock, up previously from $10.00.
Medium
Report
Evolus, Inc. (NASDAQ: EOLS) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating. They now have a $16.00 price target on the stock, up previously from $10.00.